BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy.

Objective: In this study, we aimed to investigate the predictive effect of BRCA1 , STMN1 , MAPT and TUBB3 on the prognosis of patients with non-small cell lung cancer (NSCLC).
Methods: Seventy NSCLC patients who received platinum-based chemotherapy from June 2009 to July 2011 were enrolled. The protein and mRNA levels of BRCA1 , STMN1 , MAPT and TUBB3 were determined. Survival time of the patients with NSCLC was also calculated.
Results: High expression of BRCA1 or low expression of STMN1 was associated with a better prognosis in NSCLC patients ( p <0.01). In contrast, the expression of MAPT and TUBB3 were not closely related with the prognosis of NSCLC patients( p >0.05). Furthermore, patients with high expression of BRCA1 and low expression of STMN1 have lived longer ( p <0.01).
Conclusion: BRCA1 and STMN1 were independently predictors for prognosis of NSCLCs which received cisplatin-based adjuvant chemotherapy.
Competing Interests: CONFLICTS OF INTEREST All of the authors declared that they have no conflicts interest in relation to this study.